Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

FlexWave Trial: Effekten av ekstrakorporeal sjokkbølgeterapi ved spastisitet etter slag i øvre lemmer

15. november 2026 oppdatert av: National Taiwan University Hospital

Effekter av ekstrakorporal sjokkbølge for fleksorspastisitet i øvre lemmer hos slagpasienter: en randomisert kontrollert prøvelse

Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.

Studieoversikt

Detaljert beskrivelse

This study aimed to evaluate the effects of focused Extracorporeal Shock Wave Therapy (ESWT) on upper limb flexor spasticity in stroke patients. Participants were randomized into two groups: an experimental group receiving targeted ESWT on specific forearm flexor muscles, and a control group receiving placebo treatments mimicking the shockwave therapy, with treatments administered twice weekly over two weeks for a total of four sessions.

The efficacy of the treatment was measured using a comprehensive set of assessment tools, including range of motion, hand grip strength, pain levels, spasticity scales, functional assessments, as well as measures of daily living activities, ultrasound strain elastography. The outcomes were evaluated at multiple points in time: before treatment, and 1, 4, 12, and 24 weeks after the therapy concluded, to assess both immediate and sustained effects of the treatment on upper limb function and spasticity in stroke survivors.

Studietype

Intervensjonell

Registrering (Faktiske)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Taipei, Taiwan, 100
        • Department of Physical Medicine & Rehabilitation , National Taiwan University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Individuals aged 18 years or older with unilateral cerebral stroke.
  • Wrist/finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale.
  • Stable medical condition and vital signs.
  • Conscious and able to comply with instructions.

Exclusion Criteria:

  • History of more than one stroke, traumatic brain injury, or cerebral neoplasm.
  • Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment.
  • Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers.
  • Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months.
  • Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Focused Extracorporeal Shock Wave Therapy

Participants in this arm will receive focused Extracorporeal Shock Wave Therapy (ESWT) targeting three specific muscles: the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis. Each muscle will receive 1,500 shockwave shots per session, accumulating to a total of 4,500 shots across all targeted muscles in each session. The treatment will be administered twice a week for two consecutive weeks, resulting in a total of four treatment sessions.

The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.

Placebo komparator: Placebo-Controlled Shockwave Therapy

Participants in this arm will receive placebo-controlled focused ESWT, mirroring the treatment protocol of the experimental group but without the application of active shockwaves.

The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
modified Ashworth scale (MAS)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Evaluate spasticity in individuals with neurological conditions. The scale ranges from 0, indicating no increase in muscle tone, to 4, which represents severe spasticity with affected parts rigid in flexion or extension.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
modified Tardieu scale (MTS) R2-R1 Angle
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Difference between passive range of motion (R2) and the angle of muscle catch (R1), measured in degrees. Larger values indicate greater dynamic spasticity.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Tardieu grade
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Spasticity severity (0-5); higher grades indicate greater spasticity.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
passive range of motion for the wrist and finger joints
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

the extent to which a joint can be moved without the patient actively participating in the movement

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Medical Research Council (MRC) scale
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

grades voluntary muscle strength on a 0-5 ordinal scale

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
hand grip strength
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

use dynamometer to record the maximum force applied when the patient squeezes it

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Barthel index
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

measures a person's daily living abilities, focusing on ten areas of self-care and mobility. Scores range from 0 to 100, with higher scores denoting greater independence.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Functional Independence Measure (FIM)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

assesses a patient's level of disability and tracks changes over time, with a focus on physical and cognitive functioning across 18 items, scored from 18 (total assistance required) to 126 (fully independent).

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Wolf Motor Function Test (WMFT) Functional ability score
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

assess upper extremity function in individuals with neurological impairments, using 15 functional tasks. Scoring is on a 6-point ordinal scale, ranging from 0 ("Does not attempt with upper extremity being tested," indicating severe impairment) to 5 ("Movement appears to be normal," suggesting full functionality). Lower scores indicate greater impairment.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Action Research Arm Test (ARAT)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

a standardized measure evaluating upper limb motor ability in stroke patients, scoring from 0 (no movement) to 57 (normal arm function). It assesses grasp, grip, pinch, and gross arm movement.

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
Fugl-Meyer Assessment for the Upper Extremity (FMA-UE)
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

range from 0 (complete paralysis) to 66 (full function), assessing motor recovery in post-stroke upper extremities

pre-treatment; 1, 4, 12, and 24 weeks post-treatment
ultrasound assessment
Tidsramme: pre-treatment; 1, 4, 12, and 24 weeks post-treatment

used strain elastography to assess elasticity of forearm muscles

pre-treatment; 1, 4, 12, and 24 weeks post-treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Shu-mei Yang, MD, National Taiwan University Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. april 2024

Primær fullføring (Faktiske)

31. juli 2026

Studiet fullført (Faktiske)

31. juli 2026

Datoer for studieregistrering

Først innsendt

9. april 2024

Først innsendt som oppfylte QC-kriteriene

9. april 2024

Først lagt ut (Faktiske)

15. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2025

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere